Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Telomerase and Telomeres Biology in Thyroid Cancer.

Donati B, Ciarrocchi A.

Int J Mol Sci. 2019 Jun 13;20(12). pii: E2887. doi: 10.3390/ijms20122887. Review.

2.

TERT promoter mutations in telomere biology.

Heidenreich B, Kumar R.

Mutat Res. 2017 Jan - Mar;771:15-31. doi: 10.1016/j.mrrev.2016.11.002. Epub 2016 Nov 23. Review.

PMID:
28342451
3.

The age- and shorter telomere-dependent TERT promoter mutation in follicular thyroid cell-derived carcinomas.

Liu T, Wang N, Cao J, Sofiadis A, Dinets A, Zedenius J, Larsson C, Xu D.

Oncogene. 2014 Oct 16;33(42):4978-84. doi: 10.1038/onc.2013.446. Epub 2013 Oct 21.

PMID:
24141777
4.

TERT Promoter Mutations in Thyroid Cancer.

Alzahrani AS, Alsaadi R, Murugan AK, Sadiq BB.

Horm Cancer. 2016 Jun;7(3):165-77. doi: 10.1007/s12672-016-0256-3. Epub 2016 Feb 22. Review.

PMID:
26902827
5.

Tall cell papillary thyroid carcinoma: new diagnostic criteria and mutations in BRAF and TERT.

Dettmer MS, Schmitt A, Steinert H, Capper D, Moch H, Komminoth P, Perren A.

Endocr Relat Cancer. 2015 Jun;22(3):419-29. doi: 10.1530/ERC-15-0057. Epub 2015 Apr 13.

6.

Mechanisms underlying the activation of TERT transcription and telomerase activity in human cancer: old actors and new players.

Yuan X, Larsson C, Xu D.

Oncogene. 2019 Jul 8. doi: 10.1038/s41388-019-0872-9. [Epub ahead of print] Review.

PMID:
31285550
7.

Telomerase reverse transcriptase mutations are independent predictor of disease-free survival in Middle Eastern papillary thyroid cancer.

Bu R, Siraj AK, Divya SP, Kong Y, Parvathareddy SK, Al-Rasheed M, Al-Obaisi KAS, Victoria IG, Al-Sobhi SS, Al-Dawish M, Al-Dayel F, Al-Kuraya KS.

Int J Cancer. 2018 May 15;142(10):2028-2039. doi: 10.1002/ijc.31225. Epub 2017 Dec 29.

8.

TERT promoter mutations in thyroid cancer.

Liu R, Xing M.

Endocr Relat Cancer. 2016 Mar;23(3):R143-55. doi: 10.1530/ERC-15-0533. Epub 2016 Jan 5. Review.

9.

Telomerase reverse transcriptase moonlights: Therapeutic targets beyond telomerase.

Maida Y, Masutomi K.

Cancer Sci. 2015 Nov;106(11):1486-92. doi: 10.1111/cas.12806. Epub 2015 Oct 21. Review.

10.

Telomere length, telomerase reverse transcriptase promoter mutations, and melanoma risk.

Rachakonda S, Kong H, Srinivas N, Garcia-Casado Z, Requena C, Fallah M, Heidenreich B, Planelles D, Traves V, Schadendorf D, Nagore E, Kumar R.

Genes Chromosomes Cancer. 2018 Nov;57(11):564-572. doi: 10.1002/gcc.22669. Epub 2018 Sep 11.

PMID:
30203894
11.

Telomerase promoter mutations in cancer: an emerging molecular biomarker?

Vinagre J, Pinto V, Celestino R, Reis M, Pópulo H, Boaventura P, Melo M, Catarino T, Lima J, Lopes JM, Máximo V, Sobrinho-Simões M, Soares P.

Virchows Arch. 2014 Aug;465(2):119-33. doi: 10.1007/s00428-014-1608-4. Epub 2014 Jul 22. Review.

PMID:
25048572
12.

The role of TERT promoter mutations in postoperative and preoperative diagnosis and prognosis in thyroid cancer.

Jin A, Xu J, Wang Y.

Medicine (Baltimore). 2018 Jul;97(29):e11548. doi: 10.1097/MD.0000000000011548. Review.

13.

Frequent somatic TERT promoter mutations in thyroid cancer: higher prevalence in advanced forms of the disease.

Landa I, Ganly I, Chan TA, Mitsutake N, Matsuse M, Ibrahimpasic T, Ghossein RA, Fagin JA.

J Clin Endocrinol Metab. 2013 Sep;98(9):E1562-6. doi: 10.1210/jc.2013-2383. Epub 2013 Jul 5.

14.

[Telomerase reverse transcriptase (TERT) promoter mutations in the tumors of human endocrine organs: Biological and prognostic value].

Selivanova LS, Volganova KS, Abrosimov AY.

Arkh Patol. 2016 Jan-Feb;78(1):62-69. doi: 10.17116/patol201678162-68. Review. Russian.

PMID:
27077147
15.

Telomere biology including TERT rearrangements in neuroblastoma: a useful indicator for surgical treatments.

Kawashima M, Kojima M, Ueda Y, Kurihara S, Hiyama E.

J Pediatr Surg. 2016 Dec;51(12):2080-2085. doi: 10.1016/j.jpedsurg.2016.09.042. Epub 2016 Sep 17.

PMID:
27793328
16.

TERT Promoter Mutations in Papillary Thyroid Microcarcinomas.

de Biase D, Gandolfi G, Ragazzi M, Eszlinger M, Sancisi V, Gugnoni M, Visani M, Pession A, Casadei G, Durante C, Costante G, Bruno R, Torlontano M, Paschke R, Filetti S, Piana S, Frasoldati A, Tallini G, Ciarrocchi A.

Thyroid. 2015 Sep;25(9):1013-9. doi: 10.1089/thy.2015.0101. Epub 2015 Aug 5.

PMID:
26148423
17.

Frequent somatic mutations of the telomerase reverse transcriptase promoter in ovarian clear cell carcinoma but not in other major types of gynaecological malignancy.

Wu RC, Ayhan A, Maeda D, Kim KR, Clarke BA, Shaw P, Chui MH, Rosen B, Shih IeM, Wang TL.

J Pathol. 2014 Mar;232(4):473-81. doi: 10.1002/path.4315.

18.

Transcriptional Regulation of Telomerase Reverse Transcriptase (TERT) by MYC.

Khattar E, Tergaonkar V.

Front Cell Dev Biol. 2017 Jan 26;5:1. doi: 10.3389/fcell.2017.00001. eCollection 2017. Review.

19.

A Clinical Overview of Telomerase-Associated Aberrancies in Follicular Thyroid Tumors as Diagnostic and Prognostic Markers: Tert Alert!

Juhlin CC.

Scand J Surg. 2019 May 26:1457496919850434. doi: 10.1177/1457496919850434. [Epub ahead of print]

PMID:
31131695
20.

TERT promoter mutations are associated with distant metastases in papillary thyroid carcinoma.

Gandolfi G, Ragazzi M, Frasoldati A, Piana S, Ciarrocchi A, Sancisi V.

Eur J Endocrinol. 2015 Apr;172(4):403-13. doi: 10.1530/EJE-14-0837. Epub 2015 Jan 12.

PMID:
25583906

Supplemental Content

Support Center